Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Comprehensive transcriptome analysis of human myofibroblasts with/without the JQ-1 treatment

ABSTRACT: Comprehensive transcriptome analysis of human myofibroblasts with/without the JQ-1 treatment

PROVIDER: PRJNA589865 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Comprehensive transcriptome analysis of human myofibroblasts with/without the JQ-1 treatment [mRNA]

Project description:Comprehensive transcriptome analysis of human myofibroblasts with/without the JQ-1 treatment [mRNA]

| PRJNA589871 | ENA

Comprehensive transcriptome analysis of human myofibroblasts with/without the JQ-1 treatment [mRNA]

Project description:Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that normal parenchyma is progressively replaced by fibrotic foci comprised of myofibroblasts, active differentiated fibroblasts. IPF has an overall poor prognosis with median survival ranging from 2.5 to 3.5 years. The underlying disease mechanisms in IPF are largely unknown, and there is still no effective drug that prolongs survival of patients with IPF. It has been known that JQ-1, a BET bromodomain inhibitor, prevents TGF-β-mediated fibroblast to myofibroblast differentiation. In this study, to obtain a better understanding of the molecular mechanisms underlying the effect of JQ-1 treatment on the dedifferentiation of established myofibroblasts, we performed comparative transcriptome analysis using the high-throughput RNA-seq. The CLC Genomic Workbench software was used to screen the differentially expressed transcripts. A total of 4,155 genes with a significantly differential expression in the JQ-1 treatment group as compared with the control group.

2020-07-11 | GSE140476 | GEO

Identification of microRNA expression patterns in human myofibroblasts with/without the JQ-1 treatment and/or TGF-b

Project description:Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that normal parenchyma is progressively replaced by fibrotic foci comprised of myofibroblasts, active differentiated fibroblasts. IPF has an overall poor prognosis with median survival ranging from 2.5 to 3.5 years. The underlying disease mechanisms in IPF are largely unknown, and there is still no effective drug that prolongs survival of patients with IPF. It has been known that JQ-1, a BET bromodomain inhibitor, prevents TGF-β-mediated fibroblast to myofibroblast differentiation. Moreover, JQ-1 modulates miRNAs expression in various types of cancer cell. In this study, to gain understanding of the relationship between miRNAs expression and the effect of JQ-1 on the dedifferentiation of established myofibroblast, we investigated miRNA profiles in human myofibroblasts with/without the JQ-1 treatment and/or TGF- using miRNA microarray assay.

2020-07-11 | GSE140475 | GEO

Identification of microRNA expression patterns in human myofibroblasts with/without the JQ-1 treatment and/or TGF-b

Project description:Identification of microRNA expression patterns in human myofibroblasts with/without the JQ-1 treatment and/or TGF-b

| PRJNA589870 | ENA

Comprehensive transcriptome analysis of human myofibroblasts with/without the JQ-1 treatment

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-07-13 | GSE140477 | GEO

Microcurrent-Mediated Modulation of Myofibroblasts for Cardiac Repair and Regeneration

Project description:Myofibroblasts are one of the key cell types in cardiac injuries, leading to scar tissue formation and reduced heart function. To investigate the impact of microcurrent treatment on these cells, primary rat cardiac fibroblasts were initially differentiated into myofibroblasts. Subsequently, the differentiated myofibroblasts were subjected to microcurrent treatment at 1 and 2 µA/cm2 direct current (DC) with and without polarity reversal. Microcurrent treatments resulted in distinct transcriptional signatures and improved cell behavior. The observations show signs of microcurrent-mediated reversal of myofibroblast phenotype, possibly reducing cardiac fibrosis, and providing insights for cardiac tissue repair.

2024-03-14 | GSE238154 | GEO

Cancer-derived myofibroblasts vs. non-cancer derived myofibroblasts

Project description:All samples are conditioned media from primary cultured human gastric myofibroblasts, derived from either carcinoma tissue, or adjacent non cancerous tissue. In each experiment the cancer-derived myofibroblasts are compared against the non-cancer derived myofibroblasts from the same patient. All of the experiments were samples from Patient 1, except for 648, which is from Patient 2. SILAC labelling in each case is; 567 - Methionine COFRADIC; Cancer-derived = Heavy, Non-cancer = Light 575 - N-terminal COFRADIC; Cancer-derived = Heavy, Non-cancer = Light 646 - Cancer-derived = Light, Non-cancer = Heavy 647 - Non-cancer = Heavy, Non-cancer = Light (same cell line labelled twice to create a control experiment) 648 - Cancer-derived = Heavy, Non-cancer = Light

2013-06-20 | PRD000744 | Pride

Secretomes of Cancer-Associated Myofibroblasts and Normal Tissue Myofibroblasts in hypoxia and normoxia C4PR_LIV

Project description:Cancer-associated fibroblasts are a major component of the cancer stroma. Here we focus on gastric cancer associated myofibroblasts (CAMs). CAMs secrete factors that increase the migration, invasion and proliferation of cancer cells when compared to adjacent tissue myofibroblasts (ATMs), or normal tissue myofibroblasts (NTMs). In this study we identified and quantified the proteins secreted by normoxic (21% O2) and hypoxic (1% O2) myofibroblast cells.

2019-03-04 | PXD008104 | Pride

Comprehensive transcriptome analysis of heart tissues in the sugen/hypoxia rats with/without treatment of chrysin

Project description:Comprehensive transcriptome analysis of heart tissues in the sugen/hypoxia rats with/without treatment of chrysin

| PRJNA777235 | ENA

RNA sequencing of human esophageal myofibroblasts

Project description:We report the effect of treatment of primary cultures of human esophageal myofibroblasts with acidic bile salts

2022-09-28 | GSE197318 | GEO